Skip to main content

sofosbuvir

Generic: SOFOSBUVIR·Brand: Epclusa, SOFOSBUVIR, SOVALDI

sofosbuvir: 3 clinical trials tracked.

sofosbuvir evidence translation

What we can confirm

3 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about sofosbuvir, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 1 study sponsors
Clinical Trials (3)

An Evaluation of Bemnifosbuvir-Ruzasvir (BEM/RZR) Versus Sofosbuvir-Velpatasvir (SOF/VEL) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in a Phase 3 Randomized, Controlled, Open-label Study

NCT07037277·Phase 3·AVIR
Active, not recruiting

Primary endpoint: Portion of subjects achieving HCV RNA less than the lower limit of quantitation (LLOQ) at week 24

InterventionalRandomizedsingle880 targetStarted 2025-06Completion 2027-0350 sites · Egypt, France, Germany, Greece…Atea Pharmaceuticals, Inc.

Phase 3, Randomized, Controlled, Open-label Study to Compare the Efficacy and Safety of Bemnifosbuvir-Ruzasvir Fixed-dose Combination (BEM/RZR FDC) Versus Sofosbuvir-Velpatasvir Fixed-dose Combination (SOF/VEL FDC) in Subjects With Chronic Hepatitis C Virus (HCV) Infection

NCT06868264·Phase 3·AVIR
Active, not recruiting

Primary endpoint: Proportion of subjects achieving HCV RNA less than the lower limit of quantitation (LLOQ) at study week 24.

InterventionalRandomizedsingle880 targetStarted 2025-04Completion 2026-1250 sites · United StatesAtea Pharmaceuticals, Inc.

Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC

NCT02771405·Phase 3
Completed

Primary endpoint: Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment

Interventionalopen150 enrolledStarted 2016-03Completion 2018-011 site · EgyptNational Hepatology & Tropical Medicine Research Institute